OCA
DSGN icon

Octagon Capital Advisors’s Design Therapeutics DSGN Stock Holding History

Octagon Capital Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,926
Closed -$219K – 30
2021
Q3 		$219K Sell
14,926
-235,074
-94% -$3.91M 0.05% 29
2021
Q2 		$4.97M Hold
250,000
– – 1.03% 24
2021
Q1 		$7.47M Buy
+250,000
New +$8.43M 2.82% 15

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Octagon Capital Advisors's DSGN Position: Q4 2021 in Review

Octagon Capital Advisors sold out of Design Therapeutics (DSGN) in Q4 2021, closing a stake of 14,926 shares — an estimated $219K sold.

Octagon Capital Advisors first reported a position in DSGN in Q1 2021 and held it in 3 quarters. The position peaked at $7.47M in Q1 2021. 60 funds tracked by Wall St. Rank hold DSGN as of Q4 2021.

  • Octagon Capital Advisors reported no remaining Design Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 14,926 Design Therapeutics shares in Q4 2021, an estimated $219K.
  • Octagon Capital Advisors first reported a position in Design Therapeutics in Q1 2021 and held it in 3 quarters.
  • Octagon Capital Advisors's Design Therapeutics position peaked at $7.47M in Q1 2021.
  • 60 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2021.

Based on Octagon Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.